Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Impax Asset Management

(Sharecast News) - Analysts at Berenberg lowered their target price on asset manager Impax from 440.0p to 330.0p on Tuesday as it said the group was now "navigating an uncertain market backdrop". Impax published its Q225 update on Tuesday, revealing that assets under management had decreased by roughly 26% over the period, driven by both net outflows and negative market movements.

Berenberg noted that management highlighted that it anticipates FY25 profits to be below market expectations, with market conditions highly uncertain in H2 2025, given the impact of an escalating trade war.

However, Impax also closed its acquisition of the European assets of SKY Harbor Capital Management, which should add around £1.1bn in assets under management.

"The SKY Harbor team brings new investment capabilities to Impax, including US and global short-duration high-yield credit strategies. This is part of Impax's broader focus on diversifying its offering and distribution channels, which we think will provide the business with more resilience and growth opportunities in the medium to long term," said the German bank.

Berenberg updated its forecasts, with its FY25 earnings per share estimate reducing by approximately 12% and outer years by around 19-28%, driven by factoring in Q225 figures and a decrease in its net flow expectations.

"We expect the company to continue to target a c30% adjusted PBT margin (although we forecast that it will drop below this target in FY 2025 and FY 2026 (to c25%)," it added.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.